TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01466985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets once daily for 7 days.
Study: NCT01671787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
Study: NCT00324415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
Study: NCT02147158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: Ulipristal acetate (UPA) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: Ulipristal acetate (UPA) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: Ulipristal acetate (UPA) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: Ulipristal acetate (UPA) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.
Study: NCT00877643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upstream therapy
Description: Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rhythm control
Description: Usual care for atrial fibrillation and heart failure according to the present guidelines
Study: NCT01898468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericostal Closure Technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracostal Closure Technique
Study: NCT02478411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer physiotherapy
Description: 15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: 30 minutes of conventional physiotherapy
Study: NCT00857207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
Study: NCT00324415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy \[5 weeks if given on schedule and without interruption\], maximum 54.0 Gy \[6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
Study: NCT03277183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose erythropoietin
Description: Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose erythropoietin
Description: Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
Study: NCT03713710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pap testing
Description: Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
Study: NCT03435432

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Control
Study: NCT02244437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT02147158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.
Study: NCT01417091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Study: NCT04428697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sungurtekin Technique
Description: Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sungurtekin Technique
Description: Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
Study: NCT04122703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous tibial nerve stimulation (PTNS)
Description: The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
Study: NCT00889876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin group
Description: 2000 mg/day for one year

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 times/week with a personal coach for one year. Endurance training.
Study: NCT00716014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD101
Description: TD101 is injection into a callus on the bottom of one of the patient's feet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (placebo)
Description: A normal saline solution (placebo) is injected into one of the patient's feet.
Study: NCT02502812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study: NCT02244437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT03605706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Study: NCT03957733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
Study: NCT02588183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArticFont Advance ST Cryoenergy Balloon Catheter
Description: PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
Study: NCT02760550

Intervention type: OTHER
Intervention: No intervention
Description: Participants of all three groups completed a questionnaire.

Intervention type: OTHER
Intervention: No intervention
Description: Participants of all three groups completed a questionnaire.

Intervention type: OTHER
Intervention: No intervention
Description: Participants of all three groups completed a questionnaire.
Study: NCT05494905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FST
Description: FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
Study: NCT02629952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Tea
Description: Blueberry Tea
Study: NCT01073423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: 1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 1-hour yoga sessions administered in group format 3 times per week for 8 weeks
Study: NCT01429129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Nicotine transdermal patches as per product monograph
Study: NCT03861013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional stress prevention program (GeDStress)
Description: The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
Study: NCT03204253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH + r-LH in combination
Description: 29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH alone
Description: 32 women who were stimulated with recombinant FSH alone
Study: NCT03532074

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of bowel symptoms before surgery
Description: validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of bowel symptoms before surgery
Description: validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of rectosigmoid during laparoscopy
Description: indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: follow up and assessment of bowel symptoms after surgery
Description: validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: follow up and assessment of bowel symptoms after surgery
Description: validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of rectosigmoid perfusion during robot-assisted laparoscopy
Description: indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
Study: NCT05338723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
Study: NCT01263808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Once daily (QD) via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 µg
Description: QD via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 µg
Description: QD via SDDPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/moxifloxacin
Description: Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
Study: NCT05049408

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
Description: The MMP-1 ELISA is to measure salivary MMP-1 levels of participants

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
Description: The MMP-1 ELISA is to measure salivary MMP-1 levels of participants

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
Description: The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
Study: NCT03769129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: microwave ablation
Study: NCT05638399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: 60 mg subcutaneously per 6 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: 5mg, intravenous infusion once a year
Study: NCT01936480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin 400mg once time
Study: NCT01835392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Lower limb ischemia/reperfusion cycles

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Sham placement of blood pressure cuff without inflation
Study: NCT01252823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ILR
Description: Subcutaneous implantation of ILR under local anesthesia
Study: NCT01332227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsules, Oral, 300mg, Once daily, 48 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsules, Oral, 300mg, Once daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (heat-stable)
Description: Tablets, Oral, 100 mg, Once daily, 48 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir (heat-stable)
Description: Tablets, Oral, 100 mg, Once daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Tablets, Oral, 400 mg, Twice daily, 48 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir/Emtricitabine
Description: Tablets, Oral, 300/200 mg, Once daily, 48 weeks
Study: NCT01677273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed casein
Description: 30 g protein/supplement, 4 supplements/visit

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intact casein
Description: 30 g protein/supplement, 4 supplements/visit

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intact whey protein
Description: 30 g protein/supplement, 4 supplements/visit
Study: NCT05581550

Intervention type: RADIATION
Group type: OTHER
Intervention: FDG-PET
Description: Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.

Intervention type: RADIATION
Group type: OTHER
Intervention: Galium-68 DOTATATE
Description: 200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
Study: NCT00981981

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat bran
Description: 21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3g high MW
Description: 20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4g medium MW
Description: 28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight